These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 23010052)
21. Development and optimization of polymeric nanoparticles of antitubercular drugs using central composite factorial design. Chawla R; Jaiswal S; Mishra B Expert Opin Drug Deliv; 2014 Jan; 11(1):31-43. PubMed ID: 23802585 [TBL] [Abstract][Full Text] [Related]
22. Dissolution testing of isoniazid, rifampicin, pyrazinamide and ethambutol tablets using near-infrared spectroscopy (NIRS) and multivariate calibration. de Oliveira Neves AC; Soares GM; de Morais SC; da Costa FS; Porto DL; de Lima KM J Pharm Biomed Anal; 2012 Jan; 57():115-9. PubMed ID: 21908131 [TBL] [Abstract][Full Text] [Related]
23. Spray-dried particles as pulmonary delivery system of anti-tubercular drugs: design, optimization, in vitro and in vivo evaluation. Garg T; Goyal AK; Rath G; Murthy RS Pharm Dev Technol; 2016 Dec; 21(8):951-960. PubMed ID: 26334961 [TBL] [Abstract][Full Text] [Related]
24. Incorporation of antitubercular drug isoniazid in pharmaceutically accepted microemulsion: effect on microstructure and physical parameters. Mehta SK; Kaur G; Bhasin KK Pharm Res; 2008 Jan; 25(1):227-36. PubMed ID: 17577642 [TBL] [Abstract][Full Text] [Related]
25. Alginate microspheres of isoniazid for oral sustained drug delivery. Rastogi R; Sultana Y; Aqil M; Ali A; Kumar S; Chuttani K; Mishra AK Int J Pharm; 2007 Apr; 334(1-2):71-7. PubMed ID: 17113732 [TBL] [Abstract][Full Text] [Related]
26. Osmotically regulated asymmetric capsular systems for simultaneous sustained delivery of anti-tubercular drugs. Prabakaran D; Singh P; Jaganathan KS; Vyas SP J Control Release; 2004 Mar; 95(2):239-48. PubMed ID: 14980772 [TBL] [Abstract][Full Text] [Related]
27. Stability of isoniazid, rifampin and pyrazinamide in suspensions used for the treatment of tuberculosis in children. Seifart HI; Parkin DP; Donald PR Pediatr Infect Dis J; 1991 Nov; 10(11):827-31. PubMed ID: 1749695 [TBL] [Abstract][Full Text] [Related]
28. Determination of rifampicin, isoniazid and pyrazinamide by high performance liquid chromatography after their simultaneous extraction from plasma. Smith PJ; van Dyk J; Fredericks A Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S325-8; discussion S351-2. PubMed ID: 10593712 [TBL] [Abstract][Full Text] [Related]
29. Physicochemical properties and skin permeation of Span 60/Tween 60 niosomes of ellagic acid. Junyaprasert VB; Singhsa P; Suksiriworapong J; Chantasart D Int J Pharm; 2012 Feb; 423(2):303-11. PubMed ID: 22155414 [TBL] [Abstract][Full Text] [Related]
30. Design and evaluation of enteric-coated tablets for rifampicin and isoniazid combinations. Wang Y; Liu H; Liu K; Sun J; He Z Pharm Dev Technol; 2013; 18(2):401-6. PubMed ID: 22339279 [TBL] [Abstract][Full Text] [Related]
31. Preparation and characterization of niosomes containing rifampicin for lung targeting. Jain CP; Vyas SP J Microencapsul; 1995; 12(4):401-7. PubMed ID: 8583314 [TBL] [Abstract][Full Text] [Related]
32. Rifampicin-loaded 'flower-like' polymeric micelles for enhanced oral bioavailability in an extemporaneous liquid fixed-dose combination with isoniazid. Moretton MA; Hocht C; Taira C; Sosnik A Nanomedicine (Lond); 2014 Aug; 9(11):1635-50. PubMed ID: 24410279 [TBL] [Abstract][Full Text] [Related]
33. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis]. Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568 [TBL] [Abstract][Full Text] [Related]
34. Gelatin nanocarriers as potential vectors for effective management of tuberculosis. Saraogi GK; Gupta P; Gupta UD; Jain NK; Agrawal GP Int J Pharm; 2010 Jan; 385(1-2):143-9. PubMed ID: 19819315 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of antitubercular drug-loaded surfactants as inhalable drug-delivery systems for pulmonary tuberculosis. Chimote G; Banerjee R J Biomed Mater Res A; 2009 May; 89(2):281-92. PubMed ID: 18431766 [TBL] [Abstract][Full Text] [Related]
37. Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes. Mokhtar M; Sammour OA; Hammad MA; Megrab NA Int J Pharm; 2008 Sep; 361(1-2):104-11. PubMed ID: 18577437 [TBL] [Abstract][Full Text] [Related]
38. Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoriasis: application of Box-Behnken design, in-vitro evaluation and in-vivo skin deposition study. Abdelbary AA; AbouGhaly MH Int J Pharm; 2015 May; 485(1-2):235-43. PubMed ID: 25773359 [TBL] [Abstract][Full Text] [Related]
39. Isoniazid and its toxic metabolite hydrazine induce in vitro pyrazinamide toxicity. Tostmann A; Boeree MJ; Peters WH; Roelofs HM; Aarnoutse RE; van der Ven AJ; Dekhuijzen PN Int J Antimicrob Agents; 2008 Jun; 31(6):577-80. PubMed ID: 18358703 [TBL] [Abstract][Full Text] [Related]
40. Mechanistic explanation to the catalysis by pyrazinamide and ethambutol of reaction between rifampicin and isoniazid in anti-TB FDCs. Bhutani H; Singh S; Jindal KC; Chakraborti AK J Pharm Biomed Anal; 2005 Oct; 39(5):892-9. PubMed ID: 15978767 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]